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I.  INTRODUCTION 
Fifty-year-old Michael Taffe, a former elite-level gymnast and vice president of a 
software company, received a phone call that drastically changed his life.1 He was 
told he had rheumatoid arthritis, lupus, and diabetes.2 In the following twelve years, 
Michael was diagnosed with shingles, gout, Sjögren's syndrome,3 and an episodic 
tremor which caused his left hand to spontaneously jump.4 Additionally, for the past 
nine and a half years, he has experienced a loud noise in his ears that started one 
morning and has yet to stop.5 Unable to continue working at a high-level 
management position, Michael now works at a golf course where he is better able to 
focus on his health.6 Each day, Michael takes numerous prescription biologic drugs.7 
Despite having insurance, he has already spent $12,000 this year out of his 401K 
savings account to pay drug costs not covered by his plan.8  
In a similar story, Jamie Love’s wife was diagnosed with cancer and needed a 
life-saving biologic medication that costs $100,000 per year.9 Ironically, Jaime is the 
director of Knowledge Ecology International, a non-profit organization which works 
toward improving individuals’ access to necessary medications.10 Jaime’s wife is not 
eligible for Medicare for two more years and is currently covered by his expensive 
private insurance policy which costs them more than $2,000 per month.11 Love is 
eligible to switch to Medicare, but cannot because it would leave his wife 
                                                 
 1 John Manuel Andritoe, Breaking the Cycle of Prescription Drug Costs, ATLANTIC Oct. 
9, 2012, http://www.theatlantic.com/health/archive/2012/10/breaking-the-cycle-of-
prescription-drug-costs/263370/. 
 2 Id. 
 3 Sjögren's syndrome is a chronic autoimmune disease in which a person’s white blood 
cells attack their moisture-producing glands. About Sjögren’s Syndrome, SJÖGREN'S 
SYNDROME FOUND., http://www.sjogrens.org (last visited Oct. 10, 2012). 
 4 Andritoe, supra note 1. 
 5 Andriote, supra note 1.  
 6 Andriote, supra note 1.  
 7 Michael takes  
Neurontin and Celebrex for pain; Aleve and Advil; aspirin a couple times a 
day; Irbesartan, Metopropol, Moexipril, Nifedipine, and Triamterene-HCTZ for 
blood pressure; Glipizide for diabetes; Vitamin D; Folic acid to help with hair 
falling out; Evoxac (Cevimeline) for the Sjögren's syndrome. There's 
Methotrexate (which was developed as one of the oldest cancer drugs and 
which makes him sick) and the ‘rescue’ drug Lovacin to treat the sickness. 
Once a month there is the three- to four-hour-long infusion of the biologic drug 
Remicade. 
Andriote, supra note 1.  
 8 Andriote, supra note 1.  
 9 Andriote, supra note 1.  
 10 Andriote, supra note 1.  
 11 Andriote, supra note 1.  
2014] PPACA’S FAILURE TO REGULATE EXCESSIVE COST-SHARING 101 
 
 
uninsured.12 Until the provisions of the Patient Protection and Affordable Care Act 
(PPACA)13 that ban insurers from denying coverage to persons on the basis of their 
preexisting conditions become effective in 2014, the best hope of keeping his wife 
alive is for Love to continue making the unaffordable co-payments (co-pays)14 on his 
insurance policy.15 
Similarly, Marie D'Orsaneo lives with rheumatoid arthritis. When her condition 
worsened, she was prescribed Rituxan, an expensive injectable biologic drug for 
which prior authorization from her employer was required.16 While waiting a month 
for approval, Maria’s health deteriorated so rapidly she could not continue her job as 
a physician’s assistant and needed relatives to move into her home to help her 
perform daily functions.17 Maria is struggling to afford her prescription of Rituxan 
that costs approximately $7,000 per month.18   
The Taffe, Love, and D’Orsaneo stories demonstrate an emergent problem within 
modern medicine: insurers are legally permitted to utilize unaffordable cost-sharing 
requirements, exposing policy holders to financial risk if diagnosed with a chronic 
disease that requires a biologic drug19 prescription.20 Excessive cost-sharing 
requirements, specifically excessive co-pays or coinsurance,21 defeat the basic 
purpose of health insurance of transferring risk from the insured to the insurer.22 
                                                 
 12 Andriote, supra note 1.  
 13 Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, 124 Stat. 119 (2010). 
 14 Co-payment or co-pay is defined as “a fixed amount . . . you pay for a covered health 
care service, usually when you get the service. The amount can vary by the type of covered 
health care service.” Glossary, HEALTHCARE.GOV, http://www.healthcare.gov/glossary/c/
copayment.html (last visited Oct. 10, 2012). 
 15 Id. 
 16 Kathleen Kingsbury, If You Can’t Pay: How to Get Insurance to Cover Specialty Drugs, 
NBC NEWS (Jan. 18, 2013, 12:54 PM), http://vitals.nbcnews.com/_news/2013/01/18/
16586697-if-you-cant-pay-how-to-get-insurance-to-cover-specialty-drugs. 
 17 Id. 
 18 Id. 
 19 Also known as “specialty drugs” and “biologics.” 
 20 Cost-sharing requirements are defined as “the share of costs covered by your insurance 
that you pay out of your own pocket. This term generally includes deductibles, coinsurance, 
and copayments, or similar charges, but it doesn't include premiums, balance billing amounts 
for non-network providers, or the cost of non-covered services.” Glossary, HEALTHCARE.GOV, 
www.healthcare.gov/glossary/a/acturial.html (last visited Oct. 20, 2012).  
 21 Coinsurance is defined as “your share of the costs of a covered health care service, 
calculated as a percent . . . of the allowed amount for the service.” Glossary, 
HEALTHCARE.GOV, https://www.healthcare.gov/glossary/co-insurance/ (last visited Nov. 24, 
2013). 
 22 BLACK’S LAW DICTIONARY 1205 (9th ed. 2009) (insurance is defined as a contract by 
which one party, the insurer, undertakes to indemnify another party, the insured, against risk 
of loss, damage, or liability arising from the occurrence of some specified contingency, and 
usually to defend the insured or to pay for a defense regardless of whether the insured is 
ultimately found liable). 
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Biologic drugs treat serious, complex, and chronic conditions such as cancer and 
rheumatoid arthritis.23 It is expected by 2016 that seven of the top ten prescription 
drugs will be biologic drugs.24 For employer-provided insurance, biologic drugs 
make up about seventeen percent of employers' total drug costs, though only about 
one percent of the workforce consumes them.25 The average annual price of a 
biologic drug is $24,000 and costs are expected to grow by forty percent by 2017.26  
On March 23, 2010, President Barack Obama signed the PPACA into law.27 The 
PPACA includes provisions that create a statutory pathway for litigation of patent 
issues related to "biosimilar"28 biological products, also known as follow-on 
biologics.29 Utilization of biologic drugs is increasing and is establishing itself as an 
essential component in modern medicine.30 Although the statutory pathway of the 
PPACA is intended to expedite the process of introducing more affordable 
biosimilar products to the prescription drug market, the potential savings to patients 
are minimal and the PPACA neglects a serious problem within the current insurance 
market structure.31 
This Note will discuss how the PPACA’s abbreviated approval pathway for 
biological products creates an expedited procedure to bring less expensive biologic 
drugs to the market, but ultimately fails to make those biologic drugs affordable 
because of its lack of provisions limiting insurers’ use of excessive cost-sharing 
requirements. Part II provides an overview of prescription drugs, compares biologics 
with traditional prescription drugs, and provides a brief legislative history of 
prescription drug laws. Part III analyzes the impact of the abbreviated approval 
pathway on biologic drugs’ costs to prescribed patients. It also examines the 
                                                 
 23 PHARMACY BENEFIT MANAGEMENT INSTITUTE, 2012 SPECIALTY DRUG MANAGEMENT 
REPORT (2012), available at http://www.specialtydrugbenefitreport.com/images/stories/
PBMI_2012_SDBR.pdf. 
 24 How to Get Your Health Plan to Cover Specialty Drugs, CNBC NEWS, 
http://www.cnbc.com/id/100392819 (last visited Jan. 19, 2013, 4:02 PM). The Independent 
Specialty Pharmacy Coalition reports that approximately 57 million Americans rely on 
specialty drugs. Id. 
 25 Id.  
 26 Id. 
 27 Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, 124 Stat. 119 (2010). 
 28 Biosimilar is defined as a biologic drug shown to be highly similar to a reference 
product based on data derived from analytical, animal, and clinical studies. Minor differences 
are allowed in clinically inactive components as long as no clinically meaningful differences 
exist between the proposed biosimilar and the reference product with regard to safety, purity, 
and potency. Requirements to meet the ‘no clinically meaningful differences’ standard have 
not been defined in the law and, depending on the FDA’s implementation of the biosimilar 
approval pathway, may be variable among products based on the known safety and efficacy 
profile of the reference products. Andrew D. Zelenetz et al., NCCN Biosimilars White Paper: 
Regulatory, Scientific, and Patient Safety Perspectives, 9 J. NAT’L COMPREHENSIVE CANCER 
NETWORK, S3–S4 (Supp. 4 2011).  
 29 Id. at S21 n.26.  
 30 Id. at S5. 
 31 See Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, 124 Stat. 119 (2010). 
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PPACA’s effects on biologics inclusion into health insurance plans. This Note will 
demonstrate how the PPACA continues to keep prescription biologic drugs 
unaffordable for insured patients by permitting private insurers to continue to include 
excessive cost-sharing requirements in insurance plans. Finally, Part IV proposes a 
recommendation by which the PPACA would be amended to include a modified 
version of current proposed legislation. To fully address the problem, Congress must 
formulate and enact legislation that properly protects patients from excessive out-of-
pocket costs, while balancing the insurance companies’ interests to remain 
competitive and profitable. 
II.  OVERVIEW OF PRESCRIPTION DRUGS  
 When developing a statutory standard for prescription biologic drugs on a 
national scale it is essential to have a sound understanding of the evolution of 
prescription drug legislation.  This section explains the differences between biologic 
drugs and traditional small-molecule drugs. This section then provides an overview 
of how prescription drugs are a vital component of modern medicine and describes 
the primary federal regulations created to protect patients. Lastly, this section 
discusses provisions of the PPACA that attempt to mimic the success of previous 
legislation by inducing generic biologic drug entry. 
A.  Biologic Drugs v. Traditional Small-Molecule Drugs 
Most traditional prescription drugs are made up of simple molecules mixed 
together.32 For this reason, generic versions of small-molecule drugs can be 
manufactured to be atomically identical to their reference drug.33 As a result, the 
manufacturing, marketing, and use in clinical practice of generic small-molecule 
drugs is relatively easy compared to biologic drugs.34  
In contrast, a biologic drug is “[a] substance that is made from a living organism 
or its products and is used in the prevention, diagnosis, or treatment of cancer and 
other diseases.”35 Biologics are currently prescribed to treat many conditions 
                                                 
 32 Bryan A. Liang, Regulating Follow-on Biologics, 44 HARV. J. ON LEGIS. 363, 367 
(2007) [hereinafter Regulating Follow-on Biologics]; see also Small and Large Molecules: 
Drugs on a Chemical and Biological Basis, BAYER HEALTH CARE, http://www.bayerpharma
.com/en/research-and-development/technologies/small-and-large-molecules/index.php (last 
visited October 20, 2012) [hereinafter BAYER] (“Classic drug development works with small, 
chemically manufactured active-substance molecules. One example is acetylsalicylic acid 
(ASA), aspirin's active ingredient with a molecular weight of about 180 g/mol or 180 Da. 
These small molecules can be processed into easily ingestible tablets or capsules. If the tablet 
dissolves in the gastrointestinal tract, the dissolved active substance is absorbed into the 
bloodstream via the intestinal wall. From there, the small molecules can reach almost any 
desired destination in the body because of their tiny size. Their small structure and chemical 
composition often also helps them to easily penetrate cell membranes.”).  
 33 Zelenetz, supra note 28, at S2; see also AMGEN, BIOLOGICS AND BIOSIMILARS 11, 42 
(2011), available at http://www.amgen.com/pdfs/misc/An_Introduction_on_Biologics_and_
Biosimilars.pdf [hereinafter AMGEN] (Reference drug is defined as “the innovator product that 
the biosimilar product is intended to copy.”).  
 34 AMGEN, supra note 33, at 11.  
 35 Biological Drug Definition, NAT’L CANCER INST. DICTIONARY OF CANCER TERMS, 
http://www.cancer.gov/dictionary?cdrid=426407 (last visited Jan. 2, 2014); see also Su-Ying 
Liang, et al., Medicare Formulary Coverage for Top-Selling Biologics, 27 NATURE 
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including immune system disorders, cancers, blood conditions, and neurological 
disorders.36 Biologics and biosimilars require a considerably more complex 
manufacturing process.37 The process includes proteins synthesized from living 
organisms that must be kept in life-sustaining protected environments.38 First, the 
organisms endure protein engineering to gear protein molecules to a specific task.39 
The systematic exchange of amino acids results in the biologic candidate functioning 
even better than the natural variant.40 Approximately 80,000 different variants of a 
protein can be optimized through the use of fully automated, robot-based, high-
throughput screening and the use of special testing systems.41 Consequently, 
“biologics . . . will inherently exhibit some physiochemical differences in addition to 
the varying production processes that will also modify the products . . . and therefore 
biosimilars can be close or ‘similar’ to the innovator products but will not be 
identical.”42 The science, regulatory processes, and pharmacovigilance43 mechanisms 
for these complex biological products are still in an expensive research and 
development period.44  
Biologics and traditional small-molecule drugs have similar development times, 
but relatively high manufacturing costs and other factors result in biologics being 
significantly more expensive.45 The high cost of constructing a biologic drug 
manufacturing facility and the relatively low production yield of biologic drugs 
contribute to the high cost of the drugs. In addition, it seems as though a substantial 
portion of manufacturing costs is attributable to biologic manufacturers’ average net 
profit of thirty-two percent.46 
                                                                                                                   
BIOTECHNOLOGY 1082–84  (2009), available at http://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC2845541/.  
 36 AMGEN, supra note 33, at 8; BAYER, supra note 32 (“Biologics bind to specific cell 
receptors that are associated with the disease process. Monoclonal antibodies are specialized 
in recognizing a very specific structure on the cell surface. Used in cancer therapy, they bind 
selectively – for example to the receptors of cancer cells, making it possible to mark and fight 
specific abnormal cells. Healthy cells are usually not attacked in this process, so that biologics 
often cause fewer side effects than classic chemotherapy.”). 
 37 Regulating Follow-on Biologics , supra note 32, at 367. 
 38 Regulating Follow-on Biologics, supra note 32, at 367. 
 39 BAYER, supra note 32.  
 40 BAYER, supra note 32. 
 41 BAYER, supra note 32.  
 42 Zelenetz, supra note 28, at S2.  
 43 Pharmacovigilance is defined as procedures that monitor the safety of medicines to 
detect, assess, understand, and prevent adverse effects or any other safety-related issue. 
AMGEN, supra note 33, at 42.  
 44 AMGEN, supra note 33, at 21–23. 
 45 Kate S. Gaudry, Exclusivity Strategies and Opportunities in View of the Biologics Price 
Competition and Innovation Act, 66 FOOD & DRUG L. J. 587, 587–88 (2011). 
 46 Id. at 588. 
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Biologics can be twenty times more expensive per patient than traditional small-
molecule pharmaceuticals.47 For example, the annual price of Herceptin, a biologic 
that is designed to fight against breast cancer, can exceed $40,000.48 A one-year 
supply of Rebif, a biologic drug commonly used to treat multiple sclerosis, can cost 
more than $30,000.49 The yearly price of Xelijanz, an oral biologic used to treat 
rheumatoid arthritis, is approximately $25,000.50 Most patients require recurrent and 
large doses because of chronic illnesses, compounding costs and leaving patients in a 
defenseless position.51 
B.  Prescription Drugs in Modern Medicine 
Since pharmaceuticals are an indispensable division of the modern health care 
system,52 it is not surprising that pharmaceutical companies report the largest profit 
margin of any industry worldwide.53 Pharmaceutical innovation has allowed a level 
of alleviation of human sickness and suffering inconceivable a century ago.54 
Prescription drugs help prevent cancer recurrence and can treat and reduce the risk of 
heart disease, resulting in a forty percent increase in life expectancy.55 
Alexander Flemings’ accidental discovery of penicillin led to the "therapeutic 
revolution" of the 1940s.56 World War II accelerated commercial production of 
penicillin, saving thousands of soldiers’ lives.57 Recently, prescription drugs have 
reduced the number of deaths in the United States from HIV/AIDS, helped prevent 
                                                 
 47 Parker Tresemer, Interests in the Balance FDA Regulations Under the Biologics Price 
Competition and Innovation Act, 16 UCLA J.L. & TECH. 15 (2012). 
 48 Jon Entine, FDA Balances Costs, Patient Safety in the Biologics and Personalized 
Medicine Revolution, FORBES, July 23, 2012, http://www.forbes.com/sites/jonentine/2012/
07/23/fda-balances-costs-patient-safety-in-the-biologics-and-personalized-medicine-
revolution-will-it-get-it-right-or-damage-the-miracle-industry/. 
 49 Gaudry, supra note 45, at 587.  
 50 Matthew Herper, Xeljanz, A Cheaper-but-Expensive $25,000-a-Year Pfizer Pill for 
Rheumatoid Arthritis, Gets FDA Green Light, FORBES, Nov. 6, 2012, http://www.forbes.com/
sites/matthewherper/2012/11/06/xeljanz-a-25000-pfizer-arthritis-pill-gets-fda-green-light/. 
 51 See Gaudry, supra note 45, at 588. 
 52 Paula Tironi, Pharmaceutical Pricing: A Review of Proposals to Improve Access and 
Affordability of Prescription Drugs, 19 ANNALS HEALTH L. 311, 314–15 (2010).  
 53 Luke W. Cleland, Modern Bootlegging and the Prohibition on Fair Prices: Last Call 
for The "Repeal" of Pharmaceutical Price Gouging, 15 ALB. L.J. SCI. & TECH. 183, 184 
(2004); see also ELIZABETH SIEGEL WATKINS, MEDICATING MODERN AMERICAN: PRESCRIPTION 
DRUGS IN HISTORY 1 (2007) (“With American paying more than $200 billion in 2005 for 
prescription pills, the pharmaceutical business is the most profitable in the nation.”).  
 54 Tironi, supra note 52, at 315. 
 55 Tironi, supra note 52, at 315. 
 56 WATKINS, supra note 53, at 2. 
 57 WATKINS, supra note 53, at 2. 
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cancer recurrence, and reduced the risk of heart disease.58 Americans consume more 
prescription drugs than citizens of any other nation.59 
Patients’ access to prescription medication depends on a number of factors.60 
First, patients must have access to a provider with the capability of determining the 
appropriateness of a drug and the ability to write a prescription.61 Second, patients 
must have means to finance the prescription either through self-financing or health 
insurance.62 Lastly, access requires the ability to obtain the prescription either 
through a retail pharmacy or from a mail-order pharmacy.63  
In the past, holding insurance provided sufficient protection against the high 
costs of prescription drugs, but this is not the case in modern medicine.64 Insurers are 
permitted to discriminate against some patients based on risk classification.65 In the 
context of insurance, discrimination does not automatically mean it is wrong, 
unjustifiable, or illegal.66 Risk classification is a necessary evil to avoid adverse 
selection in the insurance market.67 Insurers define adverse selection as “the process 
by which [the insured] utilize private knowledge of their own riskiness when 
deciding to buy or forgo insurance.”68 Whether the problem of adverse selection has 
been exaggerated by insurers for financial gain has been highly debated.69 
Traditionally, physicians determined what prescriptions a patient would take 
without any input from the patient.70 During the mid 1990s, the physician-patient 
                                                 
 58 Tironi, supra note 52, at 315. 
 59 WATKINS, supra note 53, at 4; see also NAT’L CENTER FOR HEALTH STATISTICS, U.S. 
DEP’T OF HEALTH AND HUMAN SERVS., HEALTH, UNITED STATES, 2012: WITH SPECIAL 
FEATURE ON EMERGENCY CARE 282–83 (2013), available at http://www.cdc.gov/nchs/data/
hus/hus12.pdf#091 (reporting that from 2007 to 2010 48.5% of persons used at least one 
prescription drug within one month, 21.7% of persons used three or more prescription drugs 
within one month, and 10.6% of persons used five or more prescription drugs within one 
month). 
 60 Tironi, supra note 52, at 316. 
 61 Tironi, supra note 52, at 316. 
 62 Tironi, supra note 52, at 316 (Insurance includes paying any premium, deductible, 
coinsurance, or co-pay.).  
 63 Tironi, supra note 52, at 316. 
 64 Tironi, supra note 52, at 316. 
 65 Joseph J. Hylak-Reinholtz & Jay R. Naftzger, Is It Time to Shed a "Tier" for Four-Tier 
Prescription Drug Formularies? Specialty Drug Tiers May Violate HIPAA's Anti-
Discrimination, 32 N. ILL. U. L. REV. 33, 45 (2011). Risk classification occurs everyday in the 
insurance world; for example, insurers charge smokers higher premiums than non-smokers. 
Id. 
 66 Id. 
 67 Id. 
 68 Peter Siegelman, Adverse Selection in Insurance Markets: An Exaggerated Threat, 113 
YALE L.J. 1223, 1223 (2004).  
 69 Id. at 1274. Neither economic theory nor empirical evidence can demonstrate that 
adverse selection is the critical problem that many courts and scholars claim. Id. 
 70 Hylak-Reinholtz & Naftzger, supra note 65, at 40. 
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relationship drastically changed regarding the choice of prescription medicine.71 
Access to information and extensive marketing by drug manufacturers provided 
patients the knowledge to demand brand-name pharmaceuticals.72 
In response to patients demanding more expensive brand-name prescription 
drugs, health insurance providers created new insurance models utilizing co-pays.73 
Co-pays provided the dual benefit of offsetting some costs of more expensive brand-
name drugs and encouraging patients to seek generic versions.74 Eventually, 
formularies started to separate prescription drugs into different tiers.75 Formularies 
share the same purpose as co-pays of encouraging patients to seek less expensive 
medications on different tiers.76  
The affordability of prescription medications is a serious problem even for 
insurance holders.77 In 2007, private health insurance covered approximately 202 
million Americans.78 Although it is most common for Americans to obtain insurance 
through their employer, the number covered by employer-sponsored insurance is 
decreasing.79 In 2005, less than fifty percent of employer-sponsored insurance 
holders participated in prescription drug coverage and only approximately sixty-four 
percent had access to outpatient prescription drug coverage.80  
In response to rising prescription drug costs, private health insurers employ 
numerous techniques to control out-patient prescription drugs costs including 
increasing enrollee cost-sharing amounts and using formularies to exclude certain 
drugs from coverage.81 Additionally, health insurers apply quantity-dispensing 
limits, require prior authorization, and use step therapy (starting with the most cost-
effective drug and progressing to more costly therapy only if necessary).82 The 
                                                 
 71 Hylak-Reinholtz & Naftzger, supra note 65, at 40. 
 72 Hylak-Reinholtz & Naftzger, supra note 65, at 40. 
 73 Hylak-Reinholtz & Naftzger, supra note 65, at 41. 
 74 Hylak-Reinholtz & Naftzger, supra note 65, at 41. 
 75 Hylak-Reinholtz & Naftzger, supra note 65, at 41.The most common structure became a 
three-tier structure. Hylak-Reinholtz & Naftzger, supra note 65, at 41. Most three-tier 
formularies follow similar pricing: Tier 1 includes only generic drugs and has the lowest co-
pay, Tier 2 includes preferred brand-name drugs without generic substitutes and has higher 
co-pays, and Tier 3 includes non-preferred brand-name drugs and has the highest co-pay. 
Hylak-Reinholtz & Naftzger, supra note 65, at 41. 
 76 Hylak-Reinholtz & Naftzger, supra note 65, at 41. 
 77 Tironi, supra note 52, at 316. 
 78 Tironi, supra note 52, at 328. 
 79 Tironi, supra note 52, at 328. 
 80 Tironi, supra note 52, at 328-29. 
 81 JANET LUNDY, KAISER FAM. FOUND., PRESCRIPTION DRUG TRENDS 1, 6 (2010), available 
at http://kaiserfamilyfoundation.files.wordpress.com/2013/01/3057-08.pdf. 
 82  Id. In 2009, 78% of workers with employer-sponsored coverage were in plans with 
multiple tiers of cost sharing for prescription drugs, almost three times the rate in 2000 (27%). 
Id. Worker copayments have steadily increased from 2000 to 2009 in all categories of 
prescription drugs: 25% for generic drugs, 80% for preferred drugs, 59% for non-preferred 
drugs, and 49% for specialty-tier drugs. Id. 
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newest cost-sharing technique employed by insurers is to limit patients to a thirty-
day supply to prove it is effective before continuing use.83  
Another growing trend is for prescription benefit designs to include a “specialty-
tier”84 or “fourth-tier” for extremely expensive specialty drugs, where co-pays are 
replaced with coinsurance.85 Medicare drug plans started using specialty-tier 
formularies (eighty-six percent of plans had specialty tiers in 2008) and the private 
insurance market followed the trend.86 In 2004, only four percent of employer-
sponsored plans offered a plan with four or more tiers.87 In 2009, this number 
jumped to ten percent and only a year later, in 2010, thirteen percent of employer-
sponsored plans included a specialty-tier prescription drug formulary.88 Specialty-
tier prescription drugs utilize coinsurance, which is typically a payment by the 
patient of twenty to thirty-three percent of the drug's cost.89   
This expensive coinsurance payment is unaffordable for most Americans as the 
monthly cost of biologic drugs can be in the tens of thousands of dollars.90 Some 
states recognize this problem and pass legislation prohibiting the use of specialty 
tiers.91 While other states including Maryland, California, Delaware, and Vermont 
are considering legislation on specialty tiers.92 Nevertheless, the small percentage of 
states that have passed this legislation only address one technique utilized by private 
insurers and do not provide patients adequate protection from other cost-sharing 
techniques. 
C.  Legislative History of Prescription Drugs 
 Federal legislation is the driving force of prescription generic drug entry 
into the pharmaceutical market. This section discusses the creation of federal 
legislation leading up to the PPACA and the creation of an abbreviated statutory 
pathway for biologic drugs. 
                                                 
 83 CNBC NEWS, supra note 24.  
 84 It is widely debated whether “specialty-tiers” are necessary to keep costs down or are 
the product of poor social policy. Hylak-Reinholtz & Naftzger, supra note 65, at 43. 
 85 Henry Grabowski et al, Implementation of the Biosimilar Pathway: Economic and 
Policy Issues, 41 SETON HALL L. REV. 511, 529 (2011); see also Liang, supra note 35, at 1083 
(stating the most common cost-sharing technique for biologic drugs is coinsurance which 
places the patient at a higher risk of financial burden than co-pays). 
 86 Tironi, supra note 52, at 329. 
 87 Hylak-Reinholtz & Naftzger, supra note 65, at 43. 
 88 Hylak-Reinholtz & Naftzger, supra note 65, at 44. 
 89 Hylak-Reinholtz & Naftzger, supra note 65, at 44. 
 90 Hylak-Reinholtz & Naftzger, supra note 65, at 44. 
 91 Position Statement - Excessive Cost-Sharing (Specialty Tiers) for High-Cost 
Medications Represent a Barrier to Patient, ARTHRITIS FOUND. (Nov. 2011), http://www.
arthritis.org/position-statatement-excessive-cost-sharing.php. In 2010, New York passed 
legislation banning insurers using specialty tiers and other states including Maryland, 
California, Delaware, and Vermont have had bills presented on specialty tiers banning. Id. 
 92 Id. 
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1.  Prior to the Patient Protection and Affordable Care Act 
Regulation of biological products began in the early 1900s when Congress 
passed the Biologics Control Act of 1902, also known as the Virus-Toxin Law.93 The 
Virus-Toxin Law gave the Food and Drug Administration's Center for Biologics 
Evaluation and Research (CBER) authority to regulate production of vaccines and 
antitoxins.94 Non-biological drugs were not federally regulated at this time.95 In 1906 
the Federal Food and Drug Act was passed, outlawing adulterated and misbranded 
foods and drugs, but made no reference to biologic products.96 
In 1938, pre-market federal regulation of traditional small-molecule drugs began 
with the Federal Food, Drug, and Cosmetic Act (FD&C Act).97 The FD&C Act 
incorporated provisions of the Virus-Toxin Law to regulate biologic drugs.98  
Between 1938 and 1962, the Food and Drug Administration (FDA) recognized some 
traditional small-molecule branded drugs as generally safe "old drugs" and allowed 
generic versions to proceed directly to marketing without having a generic drug 
manufacturer complete a new drug application (NDA)99 for the drugs.100 Key 
                                                 
 93 Biologics Control Act of 1902, Pub. L. No. 57-244, 32 Stat. 728 (1902).  
Vaccines had been around since the late 1700s, and various other biological 
products, including viruses, therapeutic serums, toxins, and anti-toxins, were 
available. Most of these products were manufactured using methods that would 
seem crude today and that created a danger of contamination . . . Following 
incidents where these two biologics were contaminated with tetanus and resulted in 
the death of children, Congress passed the Biologics Act of 1902. 
Krista Hessler Carver et al., An Unofficial Legislative History of the Biologics Price 
Competition and Innovation Act of 2009, 65 FOOD & DRUG L.J. 671, 682 (2010). 
 94 100 Years of Biologics Regulation, U.S. FOOD & DRUG ADMIN. (Apr. 9, 2009), 
http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/100YearsofBiologics
Regulation/ucm070022.htm (“The first regulations under this Act became effective on August 
21, 1903, and mandated that producers of vaccines be licensed annually for the manufacture 
and sale of vaccines, serum, and antitoxins. Manufacturing facilities also were required to 
undergo inspections, and licenses could be revoked or suspended when necessary. Production 
was to be supervised by a qualified scientist. All product labels were required to include the 
product name, expiration date, and address and license number of the manufacturer. These 
new controls marked the beginning of a basic change in America's federal public health policy 
and a steadfast commitment to the protection of public health.”).  
 95 Id. 
 96 Id. 
 97 Colleen Kelly, The Balance Between Innovation and Competition: The Hatch-Waxman 
Act, the 2003 Amendments, and Beyond, 66 FOOD DRUG L.J. 417, 419 (2011). 
 98 100 Years of Biologics Regulation, supra note 94. 
 99 New Drug Application is defined as “the vehicle through which drug sponsors formally 
propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.” New 
Drug Application (NDA), U.S. FOOD & DRUG ADMIN. (Feb. 21, 2013), http://www.fda.gov/
Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplica
tions/NewDrugApplicationNDA/.  
 100 Id.  
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changes continued from the 1960s through the early 1980s.101 After the 1962 
amendments, the FDA required the submission of safety data in a NDA for virtually 
all new drugs, including generics, prior to those drugs entering the pharmaceutical 
market.102 The FD&C Act authorized the FDA to prevent the marketing of a new 
drug if the applicant drug manufacturer could not demonstrate the drug’s safety.103  
But, the drug manufacturer could market the new drug if the FDA did not reject the 
NDA within sixty days.104  
As prescription drug costs became a problem, Congress passed the Drug Price 
Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) to 
incentivize generic drug manufacturers to enter the market.105 Under the Hatch-
Waxman Act, the FDA must list the official and proprietary name of each drug 
approved by the FDA for sale.106 A brand name drug manufacturer identifies, by 
patent number and expiration date, any associated patents or methods of using the 
drug.107 Drug names and a list of associated patents are published in the Approved 
Drug Products with Therapeutic Equivalence Evaluations document, commonly 
referred to as the "Orange Book.”108  
The Hatch-Waxman Act allows generic drug manufacturers to file an abbreviated 
new drug application (ANDA), bypassing expensive testing and relying on safety 
and effectiveness clinical-trial data in the Orange Book.109 However, the application 
must include data that the generic drug contains the same active ingredient of a drug 
that been previously FDA-approved, as listed in the Orange Book, and that the 
proposed generic product is "bioequivalent"110 to the branded drug.111 Additionally, 
generic drug manufacturers are required to file one of four possible certifications for 
each Orange Book patent listing covering the listed drug: “(I) no such patent 
information has been submitted to the FDA; (II) the patent has expired; (III) the 
patent is set to expire on a certain date; or (IV) the patent is invalid or will not be 
                                                 
 101 Carver, supra note 93, at 672. 
 102 Carver, supra note 93, at 672. 
 103 Kelly, supra note 97, at 419. 
 104 Kelly, supra note 97, at 419–20. 
 105 Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 
98 Stat. 1585 (1984). 
 106  D. Christopher Ohly & Sailesh K. Patel, The Hatch-Waxman Act: Prescriptions for 
Innovative and Inexpensive Medicines, 19 U. BALT. INTELL. PROP. L.J. 107, 115 (2011). 
 107 Id. at 115–16.  
 108 Gaudry, supra note 45, at 588. 
 109 Ohly & Patel, supra note 106, at 116. 
 110 Bioequivalent is defined as “the relationship between two preparations of the same drug 
in the same dosage form that have a similar bioavailability.” Bioequivalence Definition, FREE 
DICTIONARY, http://medical-dictionary.thefreedictionary.com/bioequivalence (last visited Oct. 
13, 2013).  
 111 Gaudry, supra note 45, at 588. 
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infringed by the manufacture, use, or sale of the” new drug for which the application 
is submitted.112  
The last certification, commonly known as Paragraph IV certification, creates 
controversy in the pharmaceutical industry.113 Paragraph IV certifications differ in 
that generic drug manufacturers attempt market entry prior to the branded drug’s 
patent expiration, compared to the other certifications which claim there are no 
existing patent rights that would prevent market entry.114 Paragraph IV certifications 
require notification to the patent holder and a detailed statement of the factual and 
legal basis of the opinion of the applicant that the patent is invalid or will not be 
infringed.115 The patent holder has forty-five days to file a patent infringement claim 
against the generic drug applicant.116 This automatically triggers a thirty-month stay 
preventing FDA approval of the ANDA from the date notice was received.117 The 
thirty-month stay may end early upon the patent expiring or a final resolution of the 
patent litigation.118 
An important provision in the Hatch-Waxman Act provides if the “first 
applicant”119 generic drug manufacturer prevails in a Paragraph IV challenge to a 
patent, that manufacturer is rewarded with 180 days of marketing exclusivity.120 
During the 180 days of market exclusivity, FDA final ANDA approval to any other 
generic pharmaceutical manufacturer is suspended.121 This 180 day marketing 
exclusivity period is an incentive in the Hatch-Waxman Act that only permits the 
branded patent holder and the successful ANDA first applicant to manufacture and 
sell the listed drug.122 
Biologics were excluded from using the abbreviated approval process under the 
Hatch-Waxman Act.123 The rationale was that the process of creating a biologic 
involved the utilization of biological material, making it difficult to effectively copy 
and detect differences with the reference drug.124 Even minor structural deviation 
                                                 
 112 Ohly & Patel, supra note 106, at 116. 
 113 Ohly & Patel, supra note 106, at 116. 
 114 Ohly & Patel, supra note 106, at 116. 
 115 Ohly & Patel, supra note 106, at 116. 
 116 Ohly & Patel, supra note 106, at 116–17. 
 117 Kelly, supra note 97, at 424. 
 118 Kelly, supra note 97, at 424. 
 119 “First Applicant” is defined as “an applicant that, on the first day on which a 
substantially complete application containing a [Paragraph IV] certification . . . is submitted 
for approval of a drug, submits a substantially complete application that contains and lawfully 
maintains a [Paragraph IV] certification . . . for the drug.” 21 U.S.C.A. § 355(j)(5)(B)(iv)(II) 
(bb) (West 2010). 
 120 Ohly & Patel, supra note 106, at 117. 
 121 Ohly & Patel, supra note 106, at 117. 
 122 Ohly & Patel, supra note 106, at 117. 
 123 Gaudry, supra note 45, at 588. 
 124 Gaudry, supra note 45, at 588. 
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may affect a product's effectiveness and safety.125 These minor structural deviations 
create a considerable risk of adverse side effects including the immune system 
attacking the biological agent.126 
2.  The Patient Protection and Affordable Care Act 
The objective of the PPACA is to “ensure that all Americans have access to 
quality, affordable health care and will create the transformation within the health 
care system necessary to contain costs.”127 As the number of Americans without 
health insurance continues to rise and premiums become unaffordable, the PPACA 
aims to reduce rising health care costs by mandating the purchase of insurance to 
certain uninsured Americans.128 Congress found medical expenses were a significant 
factor in sixty-two percent of all personal bankruptcies in the United States.129  
The PPACA now requires insurers to accept every person or employer who 
applies for coverage.130 State operated health benefit exchanges make health 
insurance available at competitive prices at one central location for potential 
consumers.131 Medicaid coverage eligibility expands to additional persons.132  
Insurance companies are prohibited from denying coverage to applicants with pre-
existing medical conditions;133 insurers have a requirement to use a community 
rating to prevent charging an increased premium to individuals with pre-existing 
illnesses.134  Insurers are prohibited from limiting the amount of coverage available 
and banned from cancelling coverage when the insured individual gets sick.135  
                                                 
 125 Gaudry, supra note 45, at 589. 
 126 Gaudry, supra note 45, at 589. 
 127 The Patient Protection and Affordable Care Act Detailed Summary, DEMOCRATIC POL’Y 
& COMM. CTR., http://www.dpc.senate.gov/healthreformbill/healthbill04.pdf (last visited Oct. 
2, 2012). 
 128 Arthur Nussbaum, Can Congress Make You Buy Health Insurance? The Affordable 
Care Act, National Health Care Reform, and the Constitutionality of the Individual Mandate, 
50 DUQ. L. REV. 411, 413–14 (2012) (“The linchpin of the Act (and the core of the 
controversy) is the individual mandate. ACA section 1501(b) requires that all applicable 
individuals and their dependents maintain minimum essential coverage starting in 2014. Those 
who fail to obtain the minimum coverage must include a ‘shared responsibility’ payment 
along with their annual federal income tax return. The shared responsibility payment is a fixed 
dollar amount penalty, and for individuals who cannot afford the coverage, the amount is 
reduced based on household income. That payment is specifically labeled as a penalty under 
the statute and not a tax.”). 
 129 Id. at 412–13. 
 130 Id. at 413. 
 131 Id. 
 132 Id. Individuals at or below 133% of the poverty level are eligible for Medicaid. Id. 
 133 Id. 
 134 Id. 
 135 Id. at 413–14. 
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In addition, the PPACA includes provisions provided in a part of the law known 
as the Biologics Price Competition and Innovation Act (BPCIA),136 to create an 
abbreviated licensure pathway for biosimilars that are demonstrated 
“interchangeable”137 with an FDA-licensed biological product.138 This legislation 
generally mimics the goals of the Hatch-Waxman Act, which established an 
abbreviated pathway for the approval of generic drug products under the FD&C 
Act.139  
Not surprisingly, BPCIA requires biosimilar applicants to meet relatively 
rigorous requirements due to complexity of biosimilars.140 Applicants are required to 
submit analytical, animal, and clinical studies, and must submit evidence to show the 
biosimilar has the same mechanism or mechanisms to that of the reference drug.141 
Additionally, the biosimilar manufacturer must establish the conditions of use of the 
biosimilar are the same as the reference drug including the same dosage, 
administration, and strength.142 Applicants are restricted to the use of one previously 
approved reference product per biosimilar application.143 Finally, consent to an 
inspection of the biosimilar manufacturing must be obtained.144 
BPCIA takes into consideration many areas that Hatch-Waxman did not address 
because of the complex nature of biologics.145 Biosimilars do not have to be 
chemically identical to its referenced product, but must be “interchangeable.”146 
                                                 
 136 See Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, 124 Stat. 119 (2010).  
 137 Interchangeability is defined as 
 [O]ne of the criteria that those who pay for health care, like insurers and 
government programs, use when they determine whether a similar medicine can be 
provided instead of the one prescribed for a patient by his or her doctor. In the 
chemical drug context, this is somewhat straightforward since, unlike biologics, 
copies of chemical drugs, called generic drugs, can be made. The molecule of the 
active ingredient in the generic drug must be the same as the brand drug it copied. If 
the molecule of the active ingredient is identical – as well as dosage form, 
administration route and strength – and the absorption in the body is similar enough 
to the original drug, then the FDA may determine the products are interchangeable, 
as is the case for most generic drugs.  
AMGEN, supra note 33, at 14.   
 138 Gaudry, supra note 45, at 589. 
 139 Zelenetz, supra note 28, at S5; see also Federal Food, Drug, & Cosmetic Act Pub. L. 
No. 75-717, § 501, 52 Stat. 1040, 1052-53 (1938). 
 140 Katherine N. Addison, The Impact of the Biosimilars Provision of the Health Care 
Reform Bill on Innovation Investments, 10 J. MARSHALL REV. INTELL. PROP. L. 553, 562 
(2011). 
 141 Id. 
 142 Id. 
 143 Id. 
 144 Id. 
 145 See Grabowski et al., supra note 85, at 512. 
 146 See Grabowski et al., supra note 85, at 513. 
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Section 7002(a)(4) of the PPACA states the safety standard for determining if a 
biological product is interchangeable: 
 
Upon review of an application submitted under this subsection or any 
supplement to such application, the Secretary shall determine the 
biological product to be interchangeable with the reference product if the 
Secretary determines that the information submitted in the application (or 
a supplement to such application) is sufficient to show that—(A) the 
biological product— (i) is biosimilar to the reference product; and (ii) can 
be expected to produce the same clinical result as the reference product in 
any given patient; and (B) for a biological product that is administered 
more than once to an individual, the risk in terms of safety or diminished 
efficacy of alternating or switching between use of the biological product 
and the reference product is not greater than the risk of using the reference 
product without such alternation or switch.147 
 
The FDA provides traditional brand name drug manufacturers five years of 
Orange Book data exclusivity after approval.148  In contrast, BPCIA provides brand 
name biologic drug manufacturers twelve years of data exclusivity from 
biosimilars.149  Similar to the incentive of a 180-day market exclusivity period in the 
Hatch-Waxman Act, a one-year market exclusivity period, which excludes others 
attempting to be interchangeable to a reference product, is awarded to the first 
biosimilar shown to be interchangeable.150 However, this does not keep other 
biosimilars off the market, but only applies to other interchangeable biosimilars.151 
III.  THE PPACA’S BIOLOGIC DRUG PROVISIONS 
This section identifies the factors that prevent biosimilars from enjoying the same 
success of cost saving for patients compared to traditional generic drugs. It is 
important to remember the inherent differences between traditional drugs and 
biologic drugs. Also, this section discusses how the statutory construction of the 
                                                 
 147 See Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, 124 Stat. 119 (2010). 
 148 Addison, supra note 140, at 557–58 (noting that “[i]n Europe, this ‘data exclusivity’ 
period is six or ten years, depending on the country”). 
 149 Addison, supra note 140, at 558 (stating it is unclear whether the twelve years of 
exclusivity means data exclusivity or marketing, but presently the FDA seems to imply 
Markey exclusivity). 
 150 Addison, supra note 140, at 558 (showing the market exclusivity period may extend to 
eighteen months if a final court decision or a dismissal with or without prejudice on all patents 
in suit in an action instituted by the patent holder. The market exclusivity period may extend 
up to forty-two months after approval of the first interchangeable biosimilar biological 
product if the applicant that submitted the application if the patent holder of the reference drug 
and such litigation is still ongoing within such forty-two month period or eighteen months 
after approval of the first interchangeable biosimilar biological product if the applicant has not 
been sued); see Patient Prot. and Affordable Care Act, Pub. L. No. 111–48, § 7002(a)(6), 124 
Stat. 119 (2010). 
 151 Tom Gillespie III et al., Alternative Routes to Market for Follow-on Biologics, STERN 
KESSLER GOLDSTEIN FOX (June 8, 2011), http://www.skgf.com/media/pnc/6/media.1376.pdf. 
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PPACA’s provisions regarding biologic drugs will permit private insurers to 
continue utilizing excessive cost-sharing techniques.  
A.  Biosimilars are Not a Cost-Effective Solution 
The PPACA, Title VII, Improving Access to Innovative Medical Therapies, 
Subtitle A Biologics Price Competition and Innovation, outlines the approval 
pathway for biosimilars.152 Though the legislation mimics the Hatch-Waxman Act, 
biosimilar and brand name biologics will not compete on the same level as generic 
small-molecule prescriptions drugs.153  
1.  Factors that Hinder Competition of Biosimilars 
Numerous factors hinder competition of biosimilars compared to generic small-
molecule drugs.154 Entrants to the biosimilar market face significant financial 
hurdles, including substantially higher development and manufacturing costs relative 
to small-molecule drug manufacturing and costly FDA mandatory clinical testing for 
some biosimilars.155 In addition, many biosimilars will not automatically substitute 
brand name biologics, delaying the rate at which biosimilars acquire market share.156 
This will require biosimilar manufacturers to be more aggressive in marketing and 
brand development.157   
Biosimilar manufacturers must take into account that the price differential 
between a biosimilar and the reference product at market entry and over the ensuing 
years may not be significant.158 For example, prior to the PPACA advertisement 
                                                 
 152 See Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, § 7002, 124 Stat. 119 
(2010).  
 153 Under The Microscope: Impact of Abbreviated Approval Pathway for Follow-on 
Biologics, ICEMILLER LLP (Sept. 8, 2011), http://www.icemiller.com/publication_detail/id/
1732/index.aspx; see Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, § 7002, 124 
Stat. 119 (2010); see also Gaudry, supra note 45, at 589 (“Since enactment of the Hatch-
Waxman Act . . . the prices of generic drugs are approximately 60% or less that of brand-
name drugs. In total, it has been estimated that a generic-drug market offers a savings of $8 
billion to $10 billion in  a single year.”); see also Tresemer, supra note 47, at 7 (“Ultimately, 
the Hatch-Waxman Act addressed the inherent tension between promoting drug discovery and 
innovation through patent protection and a need to increase market entry of lower-cost generic 
pharmaceuticals. Between its enactment in 1984 and mid-2007, use of generic 
pharmaceuticals increased from 19% of all prescriptions to 67%. This marked increase in 
generic pharmaceuticals established the Hatch-Waxman Act as a highly successful tool for 
providing cost savings to consumers while continuing to encourage pharmaceutical 
innovation.”). 
 154 Tresemer, supra note 47, at 10. 
 155 Joseph A. DiMasi & Henry G. Grabowski, The Cost of Biopharmaceutical R&D: Is 
Biotech Different?, 28 H. MANAGE DECIS. ECON., 469, 469–79 (2007) (noting besides 
substantial overhead costs, the process for a single, successful product development takes 
between ten and fifteen years and costs on average $1.2 billion); Gaudry, supra note 45, at 
588. 
 156 Tresemer supra note 47, at 9. 
 157 Tresemer supra note 47, at 7. 
 158 Frank Kopenski Jr., Understanding Biosimilars and Projecting the Cost Savings to 
Employers, MILLIMAN CLIENT REPORT (Dec. 2011), 
116 JOURNAL OF LAW AND HEALTH [Vol. 27:99 
 
 
spending for prescription drugs was 1.5 times greater in 2009 at $10.9 billion 
compared to $6.6 billion in 1999.159 Additionally, safety and efficacy concerns of 
biosimilars may lead physicians to be reluctant to substitute a biosimilar for a brand 
name biologic.160  
The extent to which patients accept the physician-recommended biosimilars may 
hinder cost-savings.161  The future trends in specialty and biosimilar drug utilization 
and the percentage of new patients using biologics for the first time to treat existing 
or newly diagnosed healthcare conditions are other factors to be considered.162 In a 
Milliman client report, one of the world's largest providers of actuarial and related 
products and services, demand of biosimilars is more inelastic compared to 
traditional small-molecule drugs.163 In that report, a fifty-dollar co-pay differential 
did not change the utilization of biosimilars to reflect greater demand for less 
expensive biosimilars.164  
2.  Minimal Savings to Patients 
The Congressional Budget Office (CBO) estimates that from 2010 to 2019 the 
abbreviated biosimilar pathway will reduce federal budget deficits by seven billion 
dollars.165  From 2009 to 2018, biologic drug spending will be reduced by an 
estimated twenty-five billion dollars, accounting for roughly 0.5% of national 
spending on prescription drugs.166 This translates into projected discounts of 
biosimilars of only ten to thirty percent of the brand name biologic’s price.167  
Furthermore, projections also find brand name biologics will likely retain seventy to 
ninety percent of their market share after biosimilar entry.168 The overall savings for 
biosimilars over brand name biologics will be small and will not become prevalent 
until 2016, which cannot be classified as “affordable” health care for patients 
treating a disease with a biologic drug.169  
Milliman reports projections based on empirical data will lead to minimal 
savings.170 Milliman presents a best-case scenario and a more realistic scenario for 
projected savings of biosimilars: 
                                                                                                                   
http://publications.milliman.com/publications/health-published/pdfs/understanding-
biosimilars.pdf. 
 159 LUNDY, supra note 81, at 4. 
 160 LUNDY, supra note 81, at 4. 
 161 Kopenski, supra note 158, at 10.  
 162 Kopenski, supra note 158, at 10. 
 163 Kopenski, supra note 158, at 19. 
 164 Kopenski, supra note 158, at 19. 
 165 See Grabowski et al., supra note 85, at 544.  
 166 See Grabowski et al., supra note 85, at 545.  
 167 See Grabowski et al., supra note 85, at 545; see also Kopenski, supra note 158, at 13. 
 168 Kopenski, supra note 158 at 7. 
 169 Kopenski, supra note 158, at 20. 
 170 Kopenski, supra note 158, at 6. 
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If a biosimilar was introduced for every chronic healthcare condition 
immediately and all patients used a biosimilar product that was thirty 
percent cheaper, the total covered healthcare costs would decrease by one 
percent in 2011. A more realistic savings would be lower than one 
percent, especially if we consider 2011 to be year one and the fact that the 
average employer does not contribute one hundred percent to the cost of 
member healthcare coverage. Thus, some of the savings would be 
reflected in the employee share of the employer healthcare premium.171 
 
The report assumes biosimilars will be thirty percent cheaper than brand-name 
biologics.172 Although this is the highest projection in relation to the CBO’s 
projected savings, it translates into a less than one percent decrease in total 
healthcare costs.173 If it comes to fruition that thirty percent is an over-projection, 
total healthcare costs savings will be negligible.174 
B.  PPACA’s Negative Affect on Prescription Biologic Drug Coverage 
Sections 1302 and 3307 of the PPACA negatively impact prescription biologic 
drug coverage because of their vague statutory requirements.175 In particular, 
omitting the mandatory inclusion of biologic drugs into the essential health benefits 
and the metal tiers of coverage design invites insurers to continue keeping patients, 
like members the Taffe, Love, and D’Orsaneo families, unprotected. 
1.  Metal Tiers of Coverage & Essential Health Benefits 
The PPACA, section 1302(d) Levels Of Coverage, outlines how health insurers 
must offer plans within health insurance exchanges that meet distinct levels of 
coverage titled “metal tiers”: bronze, silver, gold and platinum.176 The metal tiers 
coverage are based on the percentage of full actuarial value177 of benefits the plan is 
designed to provide, and are as follows: platinum ninety percent, gold eighty percent, 
sliver seventy percent, and bronze sixty percent.178 Plans with lower actuarial values 
                                                 
 171 Kopenski, supra note 158, at 16. 
 172 Kopenski, supra note 158, at 17. 
 173 Kopenski, supra note 158, at 17.  
 174 Kopenski, supra note 158, at 17.  
 175 Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, §§ 1302, 3307, 124 Stat. 119 
(2010).  
 176 See id. § 1302(d). 
 177 Glossary, HEALTHCARE.GOV, www.healthcare.gov/glossary/a/acturial.html (last visited 
Oct. 20, 2012) (Actuarial value is defined as “the percentage of total average costs for covered 
benefits that a plan will cover. For example, if a plan has an actuarial value of 70%, on 
average, you would be responsible for 30% of the costs of all covered benefits. However, you 
could be responsible for a higher or lower percentage of the total costs of covered services for 
the year, depending on your actual health care needs and the terms of your insurance policy.”). 
 178 LARRY LEVITT & GARY CLAXTON, KAISER FAM. FOUND., WHAT THE ACTUARIAL VALUES 
IN THE AFFORDABLE CARE ACT MEAN 1, 2 n.1 (2011), available at http://www.kff.org/
healthreform/upload/8177.pdf  (“The ACA permits insurers to sell a lower actuarial value 
Catastrophic Plan in the non-group market to individuals who: (1) are under the age of 30; or 
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will have a lower premium, since the patient will have higher cost-sharing.179  The 
percentages stated are general guidelines, and the percentage actually paid will 
depend on health care services used and the details of the cost-sharing within the 
plan.180  
The PPACA also establishes “Essential Health Benefits” (EHB)181 which are 
defined as minimum requirements for the services covered by exchange-sold 
policies.182 Although the Secretary of the Department of Health and Human Services 
(HHS) is required to set EHB based on the “typical” employer plan, “typical” plans 
are not defined within the PPACA.183 Section 1302(b)(1) of the PPACA does specify 
that EHB shall include the category of prescription drugs, but it does not specify 
what biologic drugs will be incorporated within the category.184 Experts believe that 
some biologics will be included in EHB, but limited options are expected.185 
Section 1302(c) of the PPACA places annual limitations on cost-sharing for 
patients: 
 
(A) 2014.—The cost-sharing incurred under a health plan with respect to 
self-only coverage or coverage other than self-only coverage for a plan 
year beginning in 2014 shall not exceed the dollar amounts in effect under 
section 223(c)(2)(A)(ii) of the Internal Revenue Code of 1986 for self-
only and family coverage, respectively, for taxable years beginning in 
2014.  
(B) 2015 AND LATER.—In the case of any plan year beginning in a 
calendar year after 2014, the limitation under this paragraph shall— (i) in 
the case of self-only coverage, be equal to the dollar amount under 
subparagraph (A) for self only coverage for plan years beginning in 2014, 
increased by an amount equal to the product of that amount and the 
premium adjustment percentage under paragraph (4) for the calendar year; 
and (ii) in the case of other coverage, twice the amount in effect under 
                                                                                                                   
(2) would otherwise be exempt from the requirement under the ACA to have coverage 
because available coverage is unaffordable or enrollment in available coverage would be a 
hardship.”).  
 179 Id. at 2 
 180 Id. 
 181 Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, § 1302(b)(1), 124 Stat. 119 
(2010) (noting the ACA permits insurers to sell a lower actuarial value Catastrophic Plan in 
the non-group market to individuals who: (1) are under the age of 30; or (2) would otherwise 
be exempt from the requirement under the ACA to have coverage because available coverage 
is unaffordable or enrollment in available coverage would be a hardship).  
 182 Bruce Pyenson & Charles Scammell, “Essential Health Benefits” – What Is Typical?, 
MILLIMAN CLIENT REPORT (May 2011), http://publications.milliman.com/publications/health-
published/pdfs/essential-health-benefits.pdf. 
 183 Id. 
 184 Id. at 8. 
 185 Michael D. Dalzell, How Will Biologics Fit into Healthcare Reform?, 8 BIOTECHNICAL 
HEALTHCARE 6, 10 (2011), available at http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC3278131/. 
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clause (i). If the amount of any increase under clause (i) is not a multiple 
of $50, such increase shall be rounded to the next lowest multiple of 
$50.186 
 
The PPACA also provides that the cost-sharing annual limitation “does not 
include premiums, balance billing amounts for non-network providers, or spending 
for non-covered services.”187 This means insurers may construct insurance plans that 
to do not cover most biologic drugs because any cost after the annual cost-sharing 
limitation is incurred by the insurer.188 It is economically efficient for insurers to 
omit biologic drug coverage and leave patients exposed to the risk of paying for 
these drugs.189 
2.  Statutory Construction Invites Exclusion or Limitation  
Virtually all employees (ninety-nine percent) with healthcare coverage have a 
prescription drug benefit, which almost always covers both brand-name and generic 
drugs.190 Insurers most commonly use a three-tiered approach to prescription drug 
pricing, but there is an increasing trend for insurers to move to a four-tiered approach 
that includes a tier for high-priced or specialty drugs.191 Specialty drug tiers, which 
may be brand name or generic, usually include biologic drugs.192 Because biologics 
require special handling and are significantly more expensive to manufacture they 
are subject to different benefit coverage criteria and utilization management.193 The 
Kaiser Family Foundation reports that in 2009, “over three-quarters (seventy-eight 
percent) of workers with prescription drug coverage in plans with four tiers of drug 
coverage.”194 EHB are expected to use the same broad definitions typical in the 
industry, and will continue to allow flexibility utilizing formularies and other 
common drug cost management tools, most commonly increased co-pays or 
coinsurance.195 
Biologics not being included in the definition of EHB will lead managed care 
organizations and government programs to balance the cost of the biologic with the 
efficacy of the treatment.196 It will be hard to justify a biologic that costs $80,000 to 
fight cancer and such treatments will have a much harder time finding inclusion in a 
                                                 
 186 Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, § 1302(c), 124 Stat. 119 
(2010). 
 187 Id.  
 188 Id. 
 189 Id. 
 190 Pyenson & Scammel, supra note 182, at 3.  
 191 John Carroll, When New Drugs Are Costly, How High to Raise Copays?, MANAGED 
CARE (June 2006), http://www.managedcaremag.com/archives/0606/0606.tiers.html. 
 192 Pyenson & Scammel, supra note 182, at 8. 
 193 Pyenson & Scammel, supra note 182, at 8.  
 194 ARTHRITIS FOUND., supra note 91. 
 195 Pyenson & Scammel, supra note 182, at 8. 
 196 Dalzell, supra note 185, at 7. 
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plan.197 Section 3307 of the PPACA requires insurers offering a prescription drug 
plan to include all covered Medicare part D drugs in the categories and classes 
identified by the Secretary of HHS as categories and classes of drugs determined to 
be of clinical concern.198 Section 3307 does not establish criteria to determine drugs 
of clinical concern; instead, the statute permits the Secretary to establish her own 
criteria.199  
On December 16, 2011, the HHS issued a bulletin outlining proposed policies of 
rulemaking regarding essential health benefits.200 The bulletin took into account 
comments from the general public, as well as input from the Department of Labor, 
the Institute of Medicine, and research conducted by HHS.201 HHS Secretary, 
Kathleen Sebelius, has promised the public and many groups—including 
oncologists, manufacturers, and patient advocacy organizations that are affected by 
what EHB are consisted of—that they will be heard before HHS issues a proposed 
rule.202 However, the Secretary has unlimited discretion and may establish 
exceptions that permit insurers to exclude prescription drugs from its formulary, a 
specific covered part D drug, or to otherwise limit access to such a drug.203   
                                                 
 197 Dalzell, supra note 185, at 7. 
 198 Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, § 3307 (a)(i)(I), 124 Stat. 119 
(2010). Section 3307 improves formulary requirements for prescription drug plans and MA-
PD plans with respect to certain categories or classes of drugs. Id.  
 199 See id. at § 3307 (a)(ii)(II).  
 200 Essential Health Benefits Bulletin, CTR. FOR CONSUMER INFO. & INS. OVERSIGHT (Dec. 
16, 2011), http://www.cms.gov/CCIIO/Resources/Files/Downloads/essential_health_benefits_ 
bulletin.pdf (“To meet the EHB coverage standard, HHS intends to require that a health plan 
offer benefits that are ‘substantially equal’ to the benchmark plan selected by the state and 
modified as necessary to reflect the 10 coverage categories. Health plans also would have 
flexibility to adjust benefits, including both the specific services covered and any quantitative 
limits, provided they continue to offer coverage for all 10 statutory EHB categories and the 
coverage has the same value. Permitting flexibility will provide greater choice to consumers, 
promoting plan innovation through coverage and design options, while ensuring that plans 
providing EHBs offer a certain level of benefits.”). 
 201 Id. at 1–3. 
 202 Dalzell, supra note 185, at 7; Essential Health Benefits: Balancing Coverage and Cost, 
INST. MED. NAT’L ACADS. (Oct. 6, 2011), http://www.iom.edu/~/media/Files/Report%20Files/
2011/Essential-Health-Benefits-Balancing-Coverage-and-Cost/essentialhealthbenefitsreport
brief4.pdf  (“In both defining and updating the EHB package, the methods used by HHS 
should be highly visible and allow for current and future enrollees to help define priorities for 
coverage. As envisioned by the committee, the public deliberation process would enable 
individuals—working in small group meetings around the country—to participate in a 
prioritization process, where different elements of coverage–specific services, types of cost-
sharing, degree of provider choice, approval requirements, etc.–are discussed and debated. 
Learning from these groups will help HHS understand potential enrollees’ priorities when 
tradeoffs are necessary.”). 
 203 See, Patient Prot. & Affordable Care Act, Pub. L. No. 111–48, § 3307 (a)(i)(II), 124 
Stat. 119 (2010).  
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On November 20, 2012, the Secretary released a proposed rule204 that clarifies 
what will be included in the EHB.205 Pursuant to the proposed rule, health insurance 
plans will be required to cover “at least the greater of: (i) one drug in every United 
States Pharmacopeia (USP)206 category and class; or  (ii) the same number of 
prescription drugs in each category and class as the EHB-benchmark plan.”207  
HHS’ proposed rule of EHB includes responses to comments from the public and 
different organizations.208 A response to a comment regarding prescription drug 
coverage stated: 
 
Comment: Commenters also recommended specific uses of the data we 
proposed to collect, for example that consumers and states have access to 
the data. Several commenters urged HHS to use the data for specific 
purposes, such as to ensure that certain services are covered, that plans are 
not discriminatory, that prescription drug coverage is comparable to a 
typical employer plan and that benefit limits do not reduce actuarial value 
(AV). 
Response: We note that the purpose of the data collection in this final rule 
is to collect benefit and coverage information from potential benchmark 
plans. Accordingly, we addressed comments on potential uses of the data 
collected to the extent that they are related to the development of 
benchmark plans.209 
 
In accordance with the comment, the EHB Proposed Rule is ambiguous on its 
face. Specifically, how the requirement to cover “at least the greater of” two options 
                                                 
 204 Recognition of Entities for the Accreditation of Qualified Health Plans, 77 Fed. Reg. 
42658 (July 20, 2012) (to be codified at 45 C.F.R. pt. 156).  
 205 Essential Health Benefits Proposed Rule: Additional Detail with Few Surprises, 
MCDERMOTT, WILL & EMORY (Nov. 30, 2012), http://www.mwe.com/files/uploads/
documents/pubs/essential_health_benefits_proposed_rule_additional_detail_with_few_surpris
es.pdf.  
 206 Medicare Prescription Drug, Improvement & Modernization Act of 2003, Pub. L. No. 
108-173, § 1860, 117 Stat. 2066 (2003). In December 2003, the Medicare Prescription Drug 
Improvement and Modernization Act of 2003 (MMA) was signed into law. The United States 
Pharmacopeial Convention (USP) is named in Section 1860D–4(b) (3) (C) (ii) of the Act, 
which states  
MODEL GUIDELINES—The Secretary shall request the United States 
Pharmacopeia to develop, in consultation with pharmaceutical benefit managers and 
other interested parties, a list of categories and classes that may be used by 
prescription drug plans under this paragraph and to revise such classification from 
time to time to reflect changes in therapeutic uses of covered Part D drugs and the 
additions of new covered Part D drugs.  
Medical Model Guidelines, U.S. PHARMACOPEIAL CONVENTION, http://www.usp.org/usp-
healthcare-professionals/medicare-model-guidelines (last updated Sept. 30, 2013). 
 207 Essential Health Benefits Proposed Rule, supra note 205, at 3. 
 208 Essential Health Benefits Proposed Rule, supra note 205, at 1. 
 209 Recognition of Entities for the Accreditation of Qualified Health Plans, 77 Fed. Reg. 
42658 (July 20, 2012) (to be codified at 45 C.F.R. pt. 156). 
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will be implemented is unclear.210 HHS released commentary to clarify the 
interpretation: “where the benchmark plan does not include coverage in a USP 
category and class, pursuant to proposed section 156.120, one drug would have to be 
offered in that USP category and class.”211 This means that the two options are not to 
be treated in isolation, but plans must include at least one drug in every USP 
category and class, even if it already has the same number of prescription drugs in 
each category and class as the EHB-benchmark plan.212  
Consistent with the EHB bulletin, health insurance providers are permitted to 
substitute benefits that are “actuarially equivalent” to the benefits being replaced.213 
Substitution requires insurance providers to “submit an actuarial certification that 
any substituted benefit(s) are actuarially equivalent to the benefit(s) in the EHB-
benchmark plan.”214 However, prescription drug benefits are subject to special 
requirements.215   
Section 1302(d)(3) of the PPACA empowers the Secretary of HHS to establish a 
reasonable “de minimis” variation in the actuarial values (AV).216 AV is “a measure 
of the percentage of expected health care costs a health plan will cover and can be 
considered a general summary measure of health plan generosity.”217 AV calculation 
computes the ratio of the total expected payments by the plan for EHB, computed in 
accordance with the plan’s cost-sharing rules, for a standard population, over the 
total costs for EHB the standard population is expected to incur.218 AV calculators 
are expected to create plan designs, but include a range of variation to be allowed, at 
a given metal level, to balance the insurance provider’s ability to create competitive 
and simple plan designs.219  HHS intends to propose a de minimis variation of +/- 
two percentage points in AV.220 The reasonable variation is intended to strike “the 
                                                 
 210 Essential Health Benefits Proposed Rule, supra note 205, at 3. 
 211 Essential Health Benefits Proposed Rule, supra note 205, at 3. The benchmark plan is 
based on the approach established in the Children’s Health Insurance Program (CHIP). 
Essential Health Benefits Bulletin, supra note 200, at 10. 
 212 Essential Health Benefits Proposed Rule, supra note 205, at 3.  
 213 Essential Health Benefits Proposed Rule, supra note 205, at 3.  
 214 Essential Health Benefits Proposed Rule, supra note 205, at 3. “Actuarial equivalence 
for purposes of this benefit substitution policy will be determined based on the value of the 
service without regard to cost-sharing. States will retain the discretion to adopt a stricter 
standard for benefit substitution or prohibit substitution entirely.” Health Care Reform: Small 
Group Plans-Essential Health Benefits (EHB), GATEWAY FINANCIAL (Feb. 2013), 
http://www.gatewayfinancial.biz/sites/all/files/gatewayfin/attachments/Compliance%20-
%20Health%20Care%20Reform%20-%20Essential%20Health%20Benefits%2001-22-13.pdf. 
 215 Essential Health Benefits Proposed Rule, supra note 205, at 3. 
 216 Actuarial Value and Cost-Sharing Reductions Bulletin, CTR FOR MEDICARE & MEDICAID 
SERVICES (Dec. 16, 2011), http://www.cms.gov/CCIIO/Resources/Files/Downloads/Av-csr-
bulletin.pdf.  
 217 Id. at 1–2. 
 218 Id. at 2. 
 219 Id. at 8. 
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right balance between ensuring comparability of plans within each metal level and 
allowing plans the flexibility to use convenient cost-sharing metrics.”221  
States have the option to choose an EHB benchmark plan based on criteria set by 
HHS.222 The options include choosing “from the three largest small group health 
insurance products, the three largest state employee health plan options, the three 
largest federal employee health plan options, or the largest commercial HMO plan 
sold in the state.”223 The deadline for a state to select a benchmark plan was 
December 26, 2012, and after this date a plan will be selected by default.224  
The PPACA mandates that states are liable for costs when state law requires 
insurance plans to cover services beyond those defined in the EHB rule.225 However, 
that provision does not affect the years 2014 and 2015, and those additional state law 
benefits will be considered essential health benefits for those years.226  
This option results in a low standard, and the complexity of benefit design will 
decrease in relation.227 With such low standards, biologic drug coverage can be 
expected to decrease as well.228 Although, the Proposed Rule uses the Guidelines of 
                                                                                                                   
 220 Id. at 8; Essential Health Benefits Standards: Ensuring Quality, Affordable Coverage, 
CENTER FOR MEDICARE AND MEDICAID SERVICES, http://www.cms.gov/CCIIO/Resources/Fact-
Sheets-and-FAQs/ehb-2-20-2013.html (last visited Oct. 13, 2013) (“To streamline and 
standardize the calculation of AV for health insurance issuers, HHS is providing a publicly 
available AV calculator, which issuers would use to determine health plan AVs based on a 
national, standard population, as required by law. Under the proposed rule, beginning in 2015, 
HHS will accept state-specific data sets for the standard population if states choose to submit 
alternate data for the calculator. The proposed rule includes standards and considerations for 
plans with benefit designs that the AV calculator cannot easily accommodate. Consumer-
driven health plans, such as high-deductible health plans and health savings accounts, are 
compatible with the AV calculator.”). 
 221 Actuarial Value and Cost-Sharing Reductions Bulletin, supra note 216, at 8.  
 222 Essential Health Benefits: What Have States Decided for Their Benchmark?, KAISER 
FAM. FOUND. (Dec. 7, 2012), http://kff.org/health-reform/fact-sheet/quick-take-essential-
health-benefits-what-have-states-decided-for-their-benchmark/. 
 223 Id. 
 224 Id. (“The EHB benchmark defines only what benefits must be covered, not what the 
cost-sharing levels will be. Carriers will develop the cost-sharing features for the products 
they offer based on the actuarial values for the different metal level plans (bronze, silver, gold, 
and platinum) spelled out in the ACA.”).  
 225 Id. (“Twenty-six states plus the District of Columbia recommended an EHB plan or 
concluded the default plan is acceptable. So far, twenty states and the District of Columbia 
have selected a small group plan as the state’s EHB benchmark. Three states, Utah, Arizona, 
and Maryland, chose a state employee health plan as the benchmark. North Dakota, 
Connecticut, Michigan, and Vermont opted to make their state’s largest commercial HMO 
plan the EHB benchmark. Nebraska’s Governor submitted an EHB recommendation for a 
state-defined benefit plan; however, the plan was ultimately not approved by HHS.”). 
 226 Id. 
 227 Bill McGivney, Essential Health Benefits: Cancer Drugs/Biologics Not “Protected”, 
THE OBR BLOG (Dec. 14, 2012, 2:47 PM), http://www.obroncology.com/blog/2012/12/
essential-health-benefits-cancer-drugsbiologics-not-%E2%80%9Cprotected%E2%80%9D/.  
 228 Id. (“It is noteworthy that in 2012, the FDA has approved over a dozen new drugs and 
biologics as cancer therapeutics.”).  
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the USP as an organizational tool to help plans determine classes and categories of 
drugs that must be considered, updating these guidelines is not expected to occur for 
more than two years.229 
Unexpectedly, “Protected Classes” based on the Medicare Part D Drug Benefit, 
which were included in the EHB bulletin were omitted in the rule.230 This is crucial 
because this results in less protection for prescription biologic drugs listed in the 
Medicare Part D Benefit.231 HHS addressed this concern with one sentence on the 
last page of the EHB bulletin: “we do not intend to adopt the protected class of drug 
policy in Part D.”232 The bottom line is that the newly proposed rule further limits 
the access to and availability of prescription biologic drugs desperately needed by 
countless patients treating life-threatening illnesses.233 
3.  Excessive Cost-Sharing Continuing into the PPACA Era 
The PPACA does not include sufficient regulations to avert trends towards 
increased co-pays, coinsurance, and specialty tiers.234 Although the PPACA 
prohibits lifetime and annual dollar caps on insurance benefits, including caps for 
prescription drugs, it only applies to prescription drugs included in the EHB.235 
The top-selling biologic drugs of 2006 were covered by most Medicare 
prescription drug plans, but were subject to prior authorization and placed in a tier 
with the highest patient cost-sharing.236 For example, out-of-pocket costs exceeded 
$4,000 annually in all cost-sharing schemes under Medicare Part D for patients 
treating rheumatoid arthritis.237 On other prescription biologics, at preferred 
pharmacies with a co-pay, out-of-pocket costs to patients were found to be up to 
sixty dollars for a thirty-day supply.238 Many patients take multiple medications to 
treat one or multiple medical problems.239 Coinsurance, commonly at a rate of 
twenty-five percent, was found to be the most common cost-sharing method.240  
Furthermore, patient cost-sharing and utilization management requirements 
increased from 2006 to 2009.241  
                                                 
 229 Id.  
 230 Id. 
 231 Id. 
 232 Id. 
 233 Id. 
 234 ARTHRITIS FOUND., supra note 91. 
 235 Pyenson & Scammell, supra note 182, at 8. 
 236  Liang, supra note 35, at 1082; Except for diabetes drugs and trastuzumab, a cancer 
drug. Liang, supra note 35, at1082. 
 237 ARTHRITIS FOUND., supra note 91. 
 238 ARTHRITIS FOUND., supra note 91; see also Carroll, supra note 191 (noting that 
copayments for biologics are designed to be significantly higher, often running $100 or more). 
 239 ARTHRITIS FOUND., supra note 91. 
 240 ARTHRITIS FOUND., supra note 91. 
 241 See Liang, supra note 35, at 1083. 
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Current trends in biologic drug coverage suggest insurance plans in the PPACA 
era will place greater access restrictions on biologics.242 In anticipation of the 
PPACA provisions becoming applicable, payers and employers reduced access and 
increased patients’ costs.243 According to the Zitter Group, a leading business 
intelligence firm working with life science companies and managed care 
organizations on product access and reimbursement, seventy-four percent of payers 
and employers believe healthcare reform will have a significant impact on their 
costs.244 This led to “thirty-five percent of payers increasing deductibles, out-of-
pocket maximums, and nonfinancial access restrictions on biologics in 2011, and 
thirty-five percent of employers saying they would do it again in 2012.”245  
Buy-up options will likely be available for biologics excluded from the essential 
benefits package, for an additional cost.246  Buy-up options could be too expensive 
for many people, restricting access to costlier and needed benefits.247 Individuals 
entering the health market with low incomes, poor health literacy, or who are at 
greater risk for chronic, disabling, or life-threatening diseases could particularly be 
affected.248  
According to market analysts, if the copayment is greater than twenty-five 
dollars per drug patients begin to look for different options.249 Shifting costs may 
reduce access to patients, but may also reduce premiums enough to support the 
inclusion of wider biologic coverage within EHB.250 Again, the inclusion of biologic 
drugs within insurance plans depends on how the government designs EHB and if 
there are any gaps in coverage where the patient is required to cover the costs.251 
These experts are using Medicare as a blueprint to speculate on what biologics will 
be excluded from EHB.252 Other experts strongly believe HHS will design plans 
where biologic benefits are carved out of EHB.253  
                                                 
 242 See generally Dalzell, supra note 185, at 7. 
 243 Dalzell, supra note 185, at 7–8. 
 244 Dalzell, supra note 185, at 7. 
 245 Dalzell, supra note 185, at 7. 
 246 Dalzell, supra note 185, at 7. 
 247 Dalzell, supra note 185, at 7. 
 248 Dalzell, supra note 185, at 7. 
 249 Carroll, supra note 191. 
 250 Dalzell, supra note 185, at 8. 
 251 Dalzell, supra note 185, at 7–8. 
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IV.  PATIENTS NEED PROTECTION 
A.  Proposed Recommendation 
Patients need prescription biologic drug cost-sharing protection because the costs 
of prescription biologics are unaffordable for a vast amount of insured patients.254 
Without this protection, the PPACA cannot fully provide access to quality, 
affordable health care to all Americans.255 The PPACA did not address high-cost 
biologics, leaving insurers to lead the way in forming social policy.256 Based on the 
analysis above, amendments to the PPACA are necessary to properly protect 
patients.  
1.  Modify and Enact the Patients’ Access to Treatments Act of 2012 
On March 19, 2012, United States Representative David McKinley introduced a 
bill, the Patients’ Access to Treatments Act of 2012 (PATA), to Congress addressing 
the problem of insurers charging excessive co-pays, coinsurance, or other cost-
sharing requirements applicable to prescription drugs in a specialty drug tiers.257 
Representative McKinley sums up the problem in a letter addressed to his colleagues 
in which he describes how patients with chronic, disabling, and life threatening 
conditions can find some relief in biological medicines, but certain insurance 
practices are preventing access to these treatments.258 He writes, “PATA would end 
the practice of discrimination between medications with a fixed co-pay and so-called 
‘specialty drugs’ by requiring commercial health insurers to impose the same co-
payment obligations for specialty drugs as they do for Tier III medication.”259 
Section 2719B, subsection (a), of PATA places limits on cost-sharing: 
 
Requirement - A group health plan, or a health insurance issuer offering 
group or individual health insurance, that provides coverage for 
prescription drugs and uses a formulary or other tiered cost-sharing 
structure shall not impose co-payment, coinsurance, or other cost-sharing 
requirements applicable to prescription drugs in a specialty drug tier that 
exceed the dollar amount (or its equivalent) of co-payment, coinsurance, 
or other cost-sharing requirements applicable to prescription drugs in a 
                                                 
 254 See Gaudry, supra note 45, at 587; see also Regulating Follow-on Biologics, supra note 
32, at 363–64. 
 255 See ARTHRITIS FOUND., supra note 91. 
 256 James C. Robinson, Insurers’ Strategies for Managing the Use and Cost of 
Biopharmaceuticals, 25 HEALTH AFFAIRS 1205, 1206 (2006), available at 
http://content.healthaffairs.org/content/25/5/1205.full.pdf.  
 257 Patients’ Access to Treatments Act of 2012, H.R. 4209, 112th Cong. (2012). 
 258 Letter from David McKinley, Become an Original Sponsor of the Patient Access to 
Critical Treatment Act Letter (2012), available at http://www.simpletasks.org/
takeaction/PATA_Dear_Colleague.pdf#toolbar=. 
 259 Id. 
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non-preferred brand drug tier (or prescription drugs in a brand drug tier if 
there is no non-preferred brand drug tier).260  
 
This bill does not solve the problem of excessive cost-sharing requirements because 
it does not take into account that insurers and the Secretary of HHS hold the power 
to devise which drugs are included, or more importantly, excluded in formularies 
subsequent to the enactment of PPACA.261 Enacting the bill as it stands will result in 
insurance companies redesigning plans that exclude biologic drugs outright. To 
resolve the problem of formularies created with the intent of excluding biologics, an 
additional provision to the already stated requirement of PATA is needed. It calls for 
an insertion of the provision stating, “EHB will include all biologics currently under 
Medicare part D without exception and include any biologic drug costing equal to or 
less than the highest costing biologic drug covered under Medicare part D.”  
This amendment will alleviate delegating the balance of access and affordability 
and prevent the continued practice of “off-label and ineffective use, erosion of 
insurance coverage, and punitive consumer cost-sharing.”262 It will solve the issue of 
excessive cost-sharing requirements, and insurers can spread the excess cost 
throughout all policies.263 Numerous other countries already delegate this 
responsibility to governmental entities, which establish a formulary, regulate prices, 
                                                 
 260 Patients’ Access to Treatments Act of 2012, H.R. 4209, 112th Cong. (2012). The 
legislation includes a special rule, subsection (b): “if a formulary used by a group health plan 
or a health insurance issuer offering group or individual health insurance contains more than 
one non-preferred brand drug tier, then the requirements of subsection (a) shall be applied 
with respect to the non-preferred brand drug tier for which beneficiary cost-sharing is lowest.” 
Id. 
 261 FAQs About the Formulary, PRIORITY HEALTH, https://www.priorityhealth.com/
member/pharmacy/using-the-drug-list/faqs#3 (last modified Oct. 12, 2011); see also Patient 
Prot. & Affordable Care Act, Pub. L. No. 111-148, § 3307 (a)(i)(II), 124 Stat. 119, 934 
(2010). 
 262 Robinson, supra note 256, at 1216. Without amending the PPACA,  
scenario would be based on increased sophistication on the part of both insurers and 
biotechnology manufacturers. The effectiveness of insurers’ strategies could grow 
over time as insurers invest in pharmaceutical expertise, improve coding and 
information systems, rationalize distribution channels, and migrate to less 
inflationary physician payment methods. The biopharmaceutical industry could 
respond by developing products supported by studies of comparative efficacy and 
cost-effectiveness and by marketing those products only through specialists with the 
relevant expertise and appropriate incentives. 
Robinson, supra note 256, at 1216. However, this is an optimistic view that has no definite 
timeline, and there are too many patients in need of access now. Robinson, supra note 256, at 
1216. 
 263 Robinson, supra note 256, at 1216. The author does recognize more research is 
necessary due to the complexity and difficulty of balancing cost and coverage within 
insurance plans. Robinson, supra note 256, at 1216. 
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and control cost-sharing of patients.264 The United States should adopt this proven 
policy to protect patients.265 
IV.  CONCLUSION 
Even though insurers must find a balance of providing services with associated 
costs, the current statutory scheme continues to subject patients in need of life-saving 
prescription biologics to an ineffective and unaffordable insurance system.266 The 
situations of the Taffe, Love, and D’Orsaneo families are prime examples of the 
growing problem and dangers of permitting excessive cost-sharing requirements 
applicable to prescription biologics.267 Though cost-sharing requirements are 
permitted in the insurance market,268 allowing insurers to continue the use of 
excessive cost-sharing requirements is deadly to patients’ health and finances.269 
Since the early twentieth century Congress has regulated the prescription drug 
industry.270 Throughout American history new legislation has been created in 
response to emergent problems.271 Although the PPACA does address the problem 
of unaffordable biologic drugs, it attempts to fix the problem in an inefficient and 
ineffective manner. The PPACA attempts to change our current health care system 
without changing the manner in which insurers design plans. Insurance providers, 
both for-profit and non-profit, cannot operate at a loss, but the harm caused by 
excessive cost-sharing techniques outweighs any inconvenience insurers suffer from 
implementing a new strategy. 
While the underlying purposes of BPCIA provisions of the PPACA parallel those 
from the Hatch-Waxman Act, the differences between biologics and traditional 
small-molecule drugs minimize the potential impact of patient savings.272 There are 
numerous factors that hinder the performance of biosimilars compared to traditional 
generic drugs,273 most notably the steep manufacturing costs, lack of automatic 
market substitution to reference drugs, and increased safety and efficacy concerns.274 
The result is minimal savings and lower access for patients created from the new 
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PPACA statutory pathway for biosimilars.275 From the analysis above, the statutory 
construction of the PPACA, including the omission of excessive cost-sharing 
regulations and the ambiguous HHS EHB proposed rule, purports to the continued 
furtherance of these harmful practices.  
Congress should develop a statutory scheme that prohibits insurers utilizing the 
harmful practice of incorporating unreasonable cost-sharing requirements into 
insurance policies.276 Specifically, Congress should amend the PPACA, by 
modifying and enacting PATA, a bill governing excessive cost-sharing requirements 
for specialty drugs, specifically biologics. By incorporating this new language into 
the PPACA, Congress would keep the statutory scheme consistent and appropriately 
protect patients in need of prescription biologics. In doing so, Congress will further 
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